Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02743351 · ClinicalTrials.gov registry record · Phase 1
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
A Phase 1 study, sponsored by Fate Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
NCT02743351 is a Phase 1 study that has completed, run by Fate Therapeutics. The registered enrollment target is 96 participants.
The verdict
NCT02743351, a Phase 1 study, has completed, sponsored by Fate Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
Study Summary
This study is a Phase 1, non-randomized, open-label/Phase 2 randomized, blinded study of ProTmune (ex vivo programmed mobilized peripheral blood cells) versus non-programmed mobilized peripheral blood cells for allogeneic hematopoietic cell transplantation (HCT) in adult subjects aged 18 years and older with hematologic malignancies. A total of 88 study subjects were treated in the trial at approximately 15 centers in the US.
Interventions
- BIOLOGICAL ProTmune
- BIOLOGICAL Control Arm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2016-12-20 |
| Est. Completion | 2021-11-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02743351
The ClinicalTrials.gov registry entry for NCT02743351 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fate Therapeutics, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ProTmune is the first listed.
NCT02743351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02743351 about?
NCT02743351 is a clinical study titled "Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies". This study is a Phase 1, non-randomized, open-label/Phase 2 randomized, blinded study of ProTmune (ex vivo programmed mobilized peripheral blood cells) versus non-programmed mobilized peripheral blood cells for allogeneic hematopoietic cell transplantation (HCT) in adult subjects aged 18 years and o...
What is the current status of trial NCT02743351?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2016-12-20. Estimated completion is 2021-11-05.
What interventions are being tested in trial NCT02743351?
The interventions under investigation include: ProTmune (BIOLOGICAL), Control Arm (BIOLOGICAL).
Who is sponsoring clinical trial NCT02743351?
This trial is sponsored by Fate Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.